VLife discovers and develops small therapeutic agents capable of multiple mechanism of action for unmet needs and diseases with limited drug options. VLife is developing a balanced pipeline of a mix of New Chemical Entities (NCE) and New Indications (NI) for FDA approved drugs. The company has a lead NCE compound for Pancreatic Cancer and a NI candidate for diabetic wound at various stages of clinical investigations. As a faster and significantly less expensive alternative to conventional high-throughput screening, the company has developed VLife Amadeus, a virtual screening technology for automated interaction studies among multiple biological targets and chosen chemical space at a structural level, providing it with a critical differentiation in its drug discovery approach.
VLife has recently announced successful completion of pre-clinical trials for its breakthrough small molecule investigational drug Galnobax for treatment of diabetic wounds. In the preclinical trials, Galnobax has demonstrated 42% improvement in time in curing wounds in diabetic patients. The clinical trials for Galnobax are intended to begin in the first half of 2008 fiscal.
In order to rapidly progress Galnobax and company's oncology program through clinical trials, VLife has recently demerged its research division into a separate company, NovaLead Pharma Pvt. Ltd. The business model of NovaLead would be to develop its discoveries up to the proof of concept in animals and then out-license or partner with the pharmaceutical and biotechnology companies to generate revenues which are milestone and royalty driven.
VLife will continue to focus on providing cutting edge discovery software solutions to Pharmaceutical, Biotechnology, Chemical, Agriculture industries, Research Institutes and Academia.
For more information: www.vlifesciences.com
Global investors are betting big on India�s long-term growth story.India istoday one of the most attractive emerging markets across Asia with a billion plus captive consumers. Kotak Private Equity is well positioned to develop compelling local investing themes.
Through macro research, in-house analytics and frequent industry interactions, we identify industry and socio-economic trends, local consumption patterns and need-gap opportunities on an ongoing basis. With a cumulative experience of successfully investing in over 100 growth companies, we regularly refine our investment focus based on emerging trends, sectors and investment opportunities.
Our team�s past investments include backing some of India�s most successful entrepreneurs across many of the sectors mentioned above.
At Kotak Private Equity, we believe in partnering with companies, not operating them. We partner to accelerate growth through need based strategic value-addition in a variety of ways. In addition to capital, we bring our expertise, experience and commitment to create a shared vision and value.
We believe that we can never substitute an entrepreneur�s energy, passion and drive. Hence, at Kotak Private Equity, we like to complement these skills with strategic growth advice, skill enhancement and operational efficiency to disproportionally deliver on his business plan.
At Kotak Private Equity, we follow an investment process that has been developed through years of investment experience. The investment process captures the sensitivities and challenges of growing businesses in an Indian business environment as well our past experiences in dealing with Indian entrepreneurs.
Since its inception,Kotak Private Equity has been the preferred investment partner with local management teams on account of its transparent and rigorous investment process, significant value creation and strategic and timely exit.
We design bespoke investment structures for each of ourportfolio companies based on theirindividual growth requirements. We believe in patient investing through structured instrumentsthat help build partnerships with management teamsanddeliver on mutually aligned goals and incentives.